NASDAQ:UBX - Nasdaq - US91381U2006 - Common Stock - Currency: USD
NASDAQ:UBX (5/2/2025, 4:30:02 PM)
1.12
+0.02 (+1.82%)
The current stock price of UBX is 1.12 USD. In the past month the price increased by 13.13%. In the past year, price decreased by -30.43%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.33 | 351.09B | ||
AMGN | AMGEN INC | 13.55 | 151.20B | ||
GILD | GILEAD SCIENCES INC | 13.4 | 129.08B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1728.1 | 128.84B | ||
REGN | REGENERON PHARMACEUTICALS | 13.67 | 65.39B | ||
ARGX | ARGENX SE - ADR | 341.93 | 39.67B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.74B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.56B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.23B | ||
NTRA | NATERA INC | N/A | 21.18B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.72B | ||
BIIB | BIOGEN INC | 7.81 | 18.10B |
Unity Biotechnology, Inc. operates as a biotechnology company. The company is headquartered in South San Francisco, California and currently employs 16 full-time employees. The company went IPO on 2018-05-03. The firm is focused on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. The company is targeting specific biological mechanisms implicated in diseases of aging. Its core therapeutic approach targets cellular senescence, and it is advancing senolytic programs primarily in ophthalmologic disorders. The company has other programs based on other biologies of aging to include an agonistic antibody to the Tie2 receptor and a Tie2/VEGF bispecific to treat vascular eye disease. UBX1325 is its advanced drug candidate for age-related diseases of the eye, including diabetic macular edema. UBX1325 is a potent small molecule inhibitor of BCL-xL. UBX2089, an α-Klotho hormone drug candidate, is being researched for multiple neurology indications.
UNITY BIOTECHNOLOGY INC
285 East Grand Avenue
South San Francisco CALIFORNIA US
Employees: 19
Company Website: https://unitybiotechnology.com/
Investor Relations: https://ir.unitybiotechnology.com/
Phone: 16504161192
The current stock price of UBX is 1.12 USD. The price increased by 1.82% in the last trading session.
The exchange symbol of UNITY BIOTECHNOLOGY INC is UBX and it is listed on the Nasdaq exchange.
UBX stock is listed on the Nasdaq exchange.
8 analysts have analysed UBX and the average price target is 5.1 USD. This implies a price increase of 355.36% is expected in the next year compared to the current price of 1.12. Check the UNITY BIOTECHNOLOGY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
UNITY BIOTECHNOLOGY INC (UBX) has a market capitalization of 18.89M USD. This makes UBX a Nano Cap stock.
UNITY BIOTECHNOLOGY INC (UBX) currently has 19 employees.
UNITY BIOTECHNOLOGY INC (UBX) has a support level at 1.01 and a resistance level at 1.13. Check the full technical report for a detailed analysis of UBX support and resistance levels.
The Revenue of UNITY BIOTECHNOLOGY INC (UBX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the UBX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
UBX does not pay a dividend.
UNITY BIOTECHNOLOGY INC (UBX) will report earnings on 2025-05-13, after the market close.
UNITY BIOTECHNOLOGY INC (UBX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.53).
The outstanding short interest for UNITY BIOTECHNOLOGY INC (UBX) is 4.56% of its float. Check the ownership tab for more information on the UBX short interest.
ChartMill assigns a technical rating of 1 / 10 to UBX. When comparing the yearly performance of all stocks, UBX is a bad performer in the overall market: 90.08% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to UBX. UBX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months UBX reported a non-GAAP Earnings per Share(EPS) of -1.53. The EPS increased by 40% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -69.01% | ||
ROE | -400.22% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to UBX. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 14.98% and a revenue growth -100% for UBX